Measurement during fibrinolytic therapy.
作者信息
McNicol G P
出版信息
Proc R Soc Med. 1969 Nov;62(11 Part 1):1131-3. doi: 10.1177/003591576906211P127.
Abstract
摘要
相似文献
1
Measurement during fibrinolytic therapy.纤维蛋白溶解疗法期间的测量。
Proc R Soc Med. 1969 Nov;62(11 Part 1):1131-3. doi: 10.1177/003591576906211P127.
2
The activator time. A method for control of activator activity during thrombolytic therapy.活化剂时间。一种在溶栓治疗期间控制活化剂活性的方法。
Scand J Haematol. 1969;6(4):221-6.
3
[Fibrinolysis and thrombolytic therapy under laboratory control].[实验室控制下的纤维蛋白溶解与溶栓治疗]
Med Lab (Stuttg). 1966 May;19(5):108-13 contd.
4
[Fibrinolysis: kinetics of the lysis of a fibrin clot].[纤维蛋白溶解：纤维蛋白凝块溶解的动力学]
Rev Eur Etud Clin Biol. 1970 Mar;15(3):333-42.
5
[Determination of serum inhibitors of fibrinolysis by the method of "standard clots"].
Pathol Biol (Paris). 1970 Jun-Jul;18(11):687-94.
6
[Clinical use of thrombolytic agents].[溶栓药物的临床应用]
Agressologie. 1983 Nov;24(11):559-65.
7
Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.由于纤溶酶原激活物水平升高导致的遗传性纤溶异常。
Thromb Haemost. 1984 Oct 31;52(2):196-200.
8
Accumulaon of macromolecular particles in the reticuloendothelial system (RES) mediated by platelet aggregation and disaggregation.由血小板聚集和解聚介导的网状内皮系统（RES）中大分子颗粒的积累。
Thromb Diath Haemorrh. 1969 Dec 31;22(3):496-507.
9
Studies on the participation of Hageman factor in fibrinolysis.关于哈格曼因子在纤维蛋白溶解中作用的研究。
Thromb Diath Haemorrh. 1970 Oct 31;24(1):1-9.
10
[Pharmacological potentials for activating the fibrinolytic system].激活纤溶系统的药理学潜力
Z Gesamte Inn Med. 1984 May 15;39(10):209-13.
引用本文的文献
1
Study of haemostasis in nephropathies associated with pulmonary haemorrhage.与肺出血相关的肾病中的止血研究。
Int Urol Nephrol. 1972;4(3):303-16. doi: 10.1007/BF02081884.
本文引用的文献
1
Partial purification and properties of a proteolytic enzyme of human serum.人血清中一种蛋白水解酶的部分纯化及性质
J Biol Chem. 1949 Nov;181(1):431-48.
2
A new method for the determination of fibrinogen in small samples of plasma.一种测定少量血浆样本中纤维蛋白原的新方法。
J Lab Clin Med. 1951 Feb;37(2):316-20.
3
EFFECT OF ANTICOAGULANT DRUGS ON PLATELET AGGREGATION IN THE CHANDLER'S TUBE.抗凝药物对钱德勒管中血小板聚集的影响。
Lancet. 1965 Apr 3;1(7388):729-30. doi: 10.1016/s0140-6736(65)92089-1.
4
THE AGGREGATION OF BLOOD PLATELETS.血小板的聚集
J Physiol. 1963 Aug;168(1):178-95. doi: 10.1113/jphysiol.1963.sp007185.
5
Hemoglobin and related compounds as antibacterial agents.血红蛋白及相关化合物作为抗菌剂。
Lab Invest. 1958 Jan-Feb;7(1):1-8.
6
The intravascular use of streptokinase.链激酶的血管内使用。
Ann N Y Acad Sci. 1957 Aug 30;68(1):201-6; discussion 206-8. doi: 10.1111/j.1749-6632.1957.tb42626.x.
7
8
Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease.健康人群与缺血性心脏病患者的血浆纤维蛋白原和纤溶酶原水平
J Clin Pathol. 1966 Jul;19(4):352-6. doi: 10.1136/jcp.19.4.352.
9
Thrombo-embolism and increased platelet adhesiveness in post-splenectomy thrombocytosis.
Australas Ann Med. 1966 May;15(2):122-8. doi: 10.1111/imj.1966.15.2.122.
10
Thrombolytic therapy with streptokinase using a standard dosage scheme.采用标准剂量方案的链激酶溶栓治疗。
Br Med J. 1966 Feb 19;1(5485):454-6. doi: 10.1136/bmj.1.5485.454.
Zotero 插件